EXAS - NASDAQ
Exact Sciences Corporation
$104.91
+0.0000%Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
At a Glance
Live SnapshotExact Sciences Corporation Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Exact Sciences Corporation Income Statement
EXAS • NASDAQ
| Exact Sciences Corporation Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
3.2B | 2.8B | 2.5B | 2.1B | 1.8B | 1.5B | 876.3M | 454.5M | 266M | 99.4M | 39.4M | 1.8M | 4.1M | 4.1M | 4.2M | 5.3M | 4.8M | -867K | 2.9M | 4.8M | |
GROSS PROFIT | ||||||||||||||||||||
(984.2M) | (840.2M) | (737.6M) | (661.4M) | (458.8M) | (354.3M) | (216.7M) | (118M) | (79.2M) | (45.2M) | (24.5M) | (4.3M) | (0.0) | (0.0) | (24K) | (24K) | (20K) | (1K) | (1.2M) | (809K) | |
2.3B | 1.9B | 1.8B | 1.4B | 1.3B | 1.1B | 659.6M | 336.5M | 186.8M | 54.2M | 14.9M | -2.5M | 4.1M | 4.1M | 4.1M | 5.3M | 4.7M | -868K | 1.7M | 3.9M | |
OPERATING INCOME | ||||||||||||||||||||
(2.4B) | (3B) | (2B) | (2B) | (2.2B) | (1.9B) | (893.4M) | (496M) | (305.1M) | (223.2M) | (174M) | (98M) | (50.9M) | (56.8M) | (33M) | (17.1M) | (13.9M) | (8.5M) | (13.4M) | (17.4M) | |
(1.9B) | (1.7B) | (1.6B) | (1.6B) | (1.7B) | (1.1B) | (737.6M) | (427.7M) | (263M) | (189.7M) | (140.1M) | (69.3M) | (23.2M) | (14.7M) | (11M) | (8.1M) | (9.7M) | (6.5M) | (8.5M) | (10.7M) | |
(523M) | (431.2M) | (426.9M) | (394.2M) | (385.6M) | (554.1M) | (139.7M) | (68.2M) | (42.1M) | (33.5M) | (33.9M) | (28.7M) | (27.7M) | (42.1M) | (22M) | (9M) | (4.2M) | (2M) | (4.9M) | (6.7M) | |
-99.1M | -1B | -215M | -593.5M | -855.7M | -767.7M | -233.8M | -159.5M | -118.3M | -169M | -159.1M | -100.5M | -46.8M | -52.6M | -28.8M | -11.8M | -9.2M | -10M | -12.8M | -14.2M | |
PRE-TAX INCOME | ||||||||||||||||||||
(32.9M) | (32M) | (24.4M) | (13.9M) | (12.9M) | (17.1M) | (51M) | (36.8M) | (206K) | (213K) | (6K) | (51K) | (69K) | (41K) | (21K) | (20K) | (0.0) | (0.0) | (0.0) | (0.0) | |
9.9M | -32M | -24.4M | -13.9M | -12.9M | -10.5M | -27.3M | -36.8M | -206K | -213K | -6K | -51K | -69K | -41K | -21K | -20K | 119K | 232K | 0.0 | 0.0 | |
-99.9M | (868.1M) | -70M | (29.2M) | (115.2M) | (279.4M) | (16M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-104.8M | 12.5M | 13.3M | -39.1M | 13.2M | -61.4M | -172.7M | -15.6M | 3.7M | 1.8M | 1.3M | 491K | 247K | 221K | 148K | 270K | 119K | 232K | 888K | 1.3M | |
-203.9M | -1B | -201.7M | -632.6M | -842.5M | -829.1M | -406.4M | -175.1M | -114.6M | -167.2M | -157.8M | -100M | -46.5M | -52.4M | -28.7M | -11.6M | -9.1M | -9.7M | -12M | -12.9M | |
NET INCOME | ||||||||||||||||||||
(4.1M) | -7.3M | (2.4M) | -9.1M | -246.9M | -5.5M | -193.4M | (92K) | -187K | (0.0) | (0.0) | -3.7M | (0.0) | (0.0) | (0.0) | -270K | (0.0) | (0.0) | (0.0) | (0.0) | |
-207.9M | -1B | -204.1M | -623.5M | -595.6M | -823.6M | -213.1M | -175.1M | -114.4M | -167.2M | -157.8M | -100M | -46.5M | -52.4M | -28.7M | -11.6M | -9.1M | -9.7M | -12M | -12.9M |
SEC Filings
EXAS - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | March 23, 2026 | March 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 20, 2026 | March 19, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 20, 2026 | February 20, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 13, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 13, 2026 | February 13, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 10, 2026 | February 10, 2026 | 2026 | |
8-K 8-K 2025 N/A | December 29, 2025 | December 23, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 20, 2025 | November 19, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 03, 2025 | September 30, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 03, 2025 | November 03, 2025 | 2025 |
Related Guides
Continue your EXAS research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.